Larkspur Well being Acquisition Corp. Information Registration Assertion on Kind S-4 Relating to the Proposed Enterprise Mixture with ZyVersa Therapeutics

BRIDGEWATER, N.J. and WESTON, Fla., Aug. 15, 2022 /PRNewswire/ — Larkspur Well being Acquisition Corp. (NASDAQ: LSPR or “Larkspur”), a blank-check particular function acquisition firm, and ZyVersa Therapeutics, Inc. (“ZyVersa”), a medical stage specialty biopharmaceutical firm leveraging superior, proprietary applied sciences to develop product candidates that tackle unmet medical wants within the areas of renal and inflammatory ailments, are happy to announce that Larkspur has filed with the U.S. Securities and Change Fee (the “SEC”) a registration assertion on Kind S-4 (the “Registration Assertion”) in reference to the enterprise mixture settlement (the “Transaction”) between Larkspur and ZyVersa beforehand introduced on July 20, 2022.

ZyVersa Therapeutics Emblem

Larkspur has filed an S-4 registration assertion concerning the proposed enterprise mixture with ZyVersa.

The Registration Assertion accommodates a preliminary proxy assertion and prospectus in reference to the Transaction. Whereas the Registration Assertion has not but change into efficient and the data contained therein is topic to vary, it gives essential details about ZyVersa and the Transaction, together with an summary of ZyVersa’s distinctive worth proposition:

  • Two proprietary drug platforms to deal with vital unmet wants of sufferers with renal ailments (VAR 200) and inflammatory ailments (IC 100)

  • Lead renal product candidate, part 2a-ready VAR 200, mediates removing of extra intracellular lipids that contribute to kidney injury resulting in end-stage renal illness

  • Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging irritation that is pathogenic in a large number of inflammatory ailments

  • Skilled CEO, Mr. Stephen Glover, who has co-founded and led a number of biopharma firms

  • Administration crew with deep scientific, industrial, and operational expertise

Completion of the Transaction, which is anticipated to happen within the fourth quarter of 2022, is topic to the Registration Assertion being declared efficient by the SEC; approval by shareholders of Larkspur and shareholders of ZyVersa; and different closing circumstances as set forth within the definitive enterprise mixture settlement between the ZyVersa and Larkspur. Upon closing of the enterprise mixture transaction, the mixed firm is anticipated to be named ZyVersa Therapeutics, Inc., which is able to proceed to function underneath the ZyVersa administration crew, led by Stephen C. Glover, Co-Founder, Chief Government Officer, and Chairman. The mixed firm’s widespread inventory is anticipated to be listed on NASDAQ underneath ticker image “ZVSA.”

About Larkspur Well being Acquisition Corp.
Larkspur is a Particular Objective Acquisition Firm (SPAC) fashioned to establish a biopharmaceutical firm that may develop and thrive as a newly fashioned public firm and profit from Larkspur’s operational experience and a major infusion of capital. Every of Larkspur’s administration crew and board of administrators have been former administration and govt management of personal and public biopharmaceutical firms and have over 50+ years of mixture funding and operational experiences. The crew strongly believes within the progress alternatives within the biotechnology business. They’re skilled operators who search to associate with prime innovators and thinkers within the biopharmaceutical subject. As operators, their entrepreneurial method allows assist for administration groups in making impactful selections with a watch towards progress and operational excellence. For extra info, please go to

About ZyVersa Therapeutics, Inc.
ZyVersa is a medical stage specialty biopharmaceutical firm leveraging superior, proprietary applied sciences to develop product candidates that tackle unmet medical wants within the areas of renal and inflammatory ailments. ZyVersa’s improvement pipeline consists of part 2a prepared VAR 200, a ldl cholesterol efflux mediator for therapy of uncommon kidney illness, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has the potential to deal with different glomerular ailments, together with Alport Syndrome and Diabetic Kidney Illness. ZyVersa’s improvement pipeline additionally consists of IC 100, a novel inflammasome ASC inhibitor being developed to deal with a large number of inflammatory ailments. For extra info, please go to

Necessary Data for Buyers and Stockholders and The place to Discover It
In reference to the transactions described herein, Larkspur filed a registration assertion on Kind S-4 that features a proxy assertion with respect to the stockholder assembly of Larkspur and a prospectus with respect to securities of the mixed firm. After the registration assertion is asserted efficient by the SEC, the proxy assertion/prospectus will likely be despatched to all Larkspur and ZyVersa stockholders. Larkspur will even file different paperwork concerning the proposed enterprise mixture with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITIES HOLDERS OF LARKSPUR AND ZYVERSA ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND THE PARTIES TO THE PROPOSED BUSINESS COMBINATION.

Buyers and securities holders will be capable to get hold of free copies of the proxy assertion/prospectus and all different related paperwork filed or that will likely be filed with the SEC by Larkspur by the web site maintained by the SEC at As well as, the paperwork filed by Larkspur could also be obtained freed from cost from Larkspur’s web site at or by written request to [email protected] Extra details about the proposed transaction, together with a duplicate of the enterprise mixture settlement and investor presentation, will likely be offered in a Present Report on Kind 8-Okay to be filed by Larkspur with the SEC which will be accessed at in addition to on-line at

Contributors within the Solicitation
Larkspur, ZyVersa, and their respective administrators and govt officers could also be deemed to be individuals within the solicitation of proxies from Larkspur’s stockholders in reference to the proposed transaction. Details about Larkspur’s administrators and govt officers and their possession of Larkspur’s securities is ready forth in Larkspur’s Annual Report for the 12 months ended December 31, 2021, which was filed with the SEC on Kind 10-Okay, as modified or supplemented by any Kind 3 or Kind 4 filed with the SEC because the date of such submitting. Different info concerning the pursuits of the individuals within the proxy solicitation will likely be included within the proxy assertion/prospectus pertaining to the proposed Transactions when it turns into obtainable. These paperwork will be obtained freed from cost from the sources indicated above.

No Supply or Solicitation
This communication doesn’t represent a proposal to promote or the solicitation of a proposal to purchase any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction through which such supply, solicitation, or sale can be illegal previous to registration or qualification underneath the securities legal guidelines of such different jurisdiction.

Ahead Trying Statements
This press launch accommodates sure forward-looking statements throughout the which means of the federal securities legal guidelines with respect to the proposed transaction between Larkspur Well being Acquisition Corp. (“Larkspur”), and ZyVersa Therapeutics, Inc. (“ZyVersa”). All statements apart from statements of historic info contained on this press launch, together with statements concerning Larkspur or ZyVersa’s future outcomes of operations and monetary place, the amount of money anticipated to be obtainable to ZyVersa after the closing and giving impact to any redemptions by Larkspur’s stockholders, ZyVersa’s enterprise technique, potential product candidates, product approvals, analysis and improvement prices, timing and chance of success, plans and goals of administration for future operations, future outcomes of present and anticipated product candidates, and anticipated use of proceeds, are forward-looking statements. These forward-looking statements typically are recognized by the phrases “imagine,” “mission,” “anticipate,” “anticipate,” “estimate,” “intend,” “technique,” “future,” “alternative,” “plan,” “could,” “ought to,” “will,” “would,” “will likely be,” “will proceed,” “will doubtless consequence,” and comparable expressions. These forward-looking statements are topic to a lot of dangers, uncertainties and assumptions, together with, however not restricted to, the next dangers regarding the proposed transaction: the incidence of any occasion, change or different circumstances that would give rise to the termination of the Enterprise Mixture Settlement; the danger that the transaction will not be accomplished in a well timed method or in any respect, which can adversely have an effect on the value of Larkspur’s securities; the incidence of any occasion, change or different circumstances that would give rise to the termination of the Merger Settlement; the shortcoming to finish the Transactions, together with because of failure to acquire approval of the shareholders of Larkspur or different circumstances to closing within the Merger Settlement; the shortcoming to acquire or keep the itemizing of Larkspur’s widespread inventory on NASDAQ following the Transactions; the danger that the Transactions disrupt present plans and operations of ZyVersa because of the announcement and consummation of the Transactions; the flexibility to acknowledge the anticipated advantages of the Transactions, which can be affected by, amongst different issues, competitors, the flexibility of the mixed firm to develop and handle progress economically and rent and retain key workers; the dangers that ZyVersa’s product candidates in improvement fail medical trials or usually are not accepted by the U.S. Meals and Drug Administration or different relevant authorities; prices associated to the Transactions; adjustments in relevant legal guidelines or laws; the chance that Larkspur or ZyVersa could also be adversely affected by different financial, enterprise, and/or aggressive elements; and different dangers and uncertainties to be recognized within the proxy assertion/prospectus (when obtainable) regarding the Transactions, together with these underneath “Threat Elements” therein, and in different filings with the SEC made by Larkspur. Furthermore, ZyVersa operates in a really aggressive and quickly altering atmosphere. As a result of forward-looking statements are inherently topic to dangers and uncertainties, a few of which can’t be predicted or quantified and a few of that are past Larkspur’s and ZyVersa’s management, you shouldn’t depend on these forward-looking statements as predictions of future occasions. Ahead-looking statements converse solely as of the date they’re made. Readers are cautioned to not put undue reliance on forward-looking statements, and besides as required by regulation. Larkspur and ZyVersa assume no obligation and don’t intend to replace or revise these forward-looking statements, whether or not because of new info, future occasions, or in any other case. Neither Larkspur nor ZyVersa offers any assurance that both Larkspur or ZyVersa or the mixed firm will obtain its expectations.

LarkSpur Health Acquisition Corp. Logo

LarkSpur Well being Acquisition Corp. Emblem



View authentic content material to obtain multimedia:

SOURCE Larkspur Well being Acquisition Corp.; ZyVersa Therapeutics, Inc.

Previous post Hong Kong’s CBD business faces wipeout as authorities ban looms | Enterprise and Economic system
Next post Sports activities Medication Market is predicted to succeed in US$ 11.4 Billion by the tip of 2032